Diplomat selected as a limited-distribution pharmacy partner by Pfizer; Diplomat to dispense Xalkori®, Bosulif®, Sutent® and Inlyta®
FLINT, Mich. —Dec. 3, 2014—Diplomat Pharmacy Inc. (NYSE: DPLO), the nation’s largest independent specialty pharmacy, announced today that it has been selected to Pfizer Inc.’s limited-distribution panel for Xalkori®, Bosulif®, Inlyta® and Sutent®.
The four limited-distribution therapies have each received approval from the U.S. Food and Drug Administration for the treatment of specific cancers.
• Xalkori (crizotinib), oral capsule for the treatment of metastatic ALK-positive non-small cell lung cancer.
• Bosulif (bosutinib), oral tablet for the treatment of Philadelphia chromosome positive chronic myelogenous leukemia in adults with resistance or intolerance to prior therapy.
• Inlyta (axitinib), oral tablet for the treatment of advanced renal cell carcinoma, a type of kidney cancer, in patients who have not responded to other treatments.
• Sutent (sunitinib), oral capsule for the treatment of three types of cancer: advanced renal cell carcinoma, gastrointestinal stromal tumors after disease progression or intolerance to prior therapy, and pancreatic neuroendocrine tumors.
“We are proud to be selected to Pfizer’s limited-distribution panel for these four important oncology treatments,” said Gary Kadlec, president of Diplomat. “Diplomat’s high-touch, patient-centric approach to care and expertise in dispensing limited-distribution drugs supports our commitment to the distribution of these therapies in accordance with our high standards of excellence.”
Bosulif and Sutent were previously available through open distribution, with Diplomat also having access to Inlyta as a member of Pfizer’s prior limited-distribution panel for the drug.
Diplomat has access to dispense Xalkori, Bosulif, Inlyta and Sutent immediately.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including relating to Diplomat’s distribution of the drug(s) set forth above (and any implied financial impact). The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information, and these statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks include the number of patients prescribed such drug(s) currently and in the future, patient’s adherence to such drug(s), the number of distributors on panel and our relative distribution share, the timing of drug sales, the cost of such drug(s) and reimbursement rates by payors, drug competition, and the factors set forth in “Risk Factors” in Diplomat’s prospectus dated October 10, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable law, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
To learn more, visit diplomat.is.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com
Gary Rice, R.Ph., MS, MBA, CSP, Diplomat
810.768.9863 | firstname.lastname@example.org
@PharmacDailyRT @PharmacDaily: @DiplomatRx to distribute Puma Biotechnology’s new cancer drug $DPLO https://t.co/gl0v6WURVV5 days ago
@DiplomatRxNerlynx (neratinib) tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting https://t.co/vi3ACWhbfe5 days ago
@AJPB_JournalRT @AJPB_Journal: Be sure to check out our Insights page featuring videos of Cheryl Allen from @DiplomatRx discussing #RA https://t.co/qxZc…2 weeks ago
@DiplomatRxWe're with @340BCoalition this week in Washington D.C.! Come say hello.3 weeks ago
@SpecialtyPTimesRT @SpecialtyPTimes: Rheumatoid Arthritis Treatment Guidelines https://t.co/sEhe74UozC #rheumatoidarthritis @DiplomatRx3 weeks ago